IP Library › Patent Application 13852569
Patent Application
App. No. 13/852,569

USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/852,569
Abstract

The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.

Claims (18)

1 . A method of treating an excessive or undesirable permeability of lung tissue containing tight junctions comprising:

administering to a subject in need thereof a composition comprising a tight junction antagonist.

2 . A method according to claim 1 , wherein the subject is a human.

3 . (canceled)

4 . A method of claim 1 , wherein the antagonist is a peptide that comprises GGVLVQPG (SEQ ID NO: 15).

5 . A method according to claim 4 , wherein the peptide consists of GGVLVQPG (SEQ ID NO: 15).

6 . A method according to claim 1 , wherein the composition is administered in conjunction with an additional therapeutic agent.

7 . A method according to claim 6 , wherein the composition and the additional therapeutic agent are administered simultaneously.

8 . A method according to claim 6 , wherein the composition and the additional therapeutic agent are not administered simultaneously.

9 . A method according to claim 6 , wherein the composition further comprises the additional therapeutic agent.

10 . A method according to claim 6 , wherein the additional therapeutic agent is selected from the group consisting of aminosalicylates, corticosteroids, immunomodulators, antibiotics, cytokines, chemokines and biologic therapeutics.

11 . A method according to claim 1 , wherein the composition is formulated for pulmonary delivery.

12 . The method of claim 1 , wherein the subject has acute respiratory distress syndrome.

13 - 22 . (canceled)

23 . The method of claim 1 , wherein the subject has acute lung injury.

24 - 33 . (canceled)

34 . A composition formulated for pulmonary delivery comprising a peptide tight junction antagonist comprising the amino acid sequence GGVLVQPG (SEQ ID NO:15).

35 - 39 . (canceled)